PROJECT SUMMARY: IDEAL Administrative Core
Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes
that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious
disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow
complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3)
research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the
study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed
studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute
streamlined processes which facilitate productive interactions among investigators from each IDEAL Project
and Core. We will achieve this goal by pursuing the following Specific Aims (SAs):
SA1. Provide infrastructure for administrative leadership aimed at building an interactive and
collaborative working team resulting in maximal project synergy.
SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads
by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as
seminars/symposia focused on the IDEAL project.
SA3. Manage and optimize communication within our IDEAL team and between our team, the
other NIH supported IDEAL teams and the IDEAL Steering Committee.
SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by
implementing recommendations of the Conflicts Resolution Group (CRG).
SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress
reports sent to the NIH.
SA6. Protect intellectual property rights of our investigators and execute material transfer
agreements.
SA7. Implement the data management/sharing plan among investigators within and outside of our
IDEAL team.
Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to
project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AdherenceAsthmaCellsChildhoodClinicalCommunicable DiseasesCommunicationDataDevelopmentDissectionEnsureEpigenetic ProcessFundingGeographyGoalsHumanImmuneImmune responseImmunologyIn VitroInfantInfrastructureIntellectual PropertyInternationalLeadershipLifeMediatingMolecularOutcomePRTN3 genePredispositionProcessProductivityProgress ReportsProperty RightsProteomicsRecommendationResearch PersonnelResearch Project GrantsShapesStructureSystems BiologyTechnologyTeleconferencesUnited States National Institutes of HealthVaccinesWorkconflict resolutiondata managementdesignimprovedin silicointer-institutionalmaterial transfer agreementmeetingsprogramsrespiratorysymposiumsynergismtimelinetranscriptomicsvaccine responsevaccinology
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
076593722
UEI
Z1L9F1MM1RY3
Project Start Date
10-March-2022
Project End Date
28-February-2027
Budget Start Date
01-March-2025
Budget End Date
28-February-2026
Project Funding Information for 2025
Total Funding
$191,754
Direct Costs
$147,146
Indirect Costs
$44,608
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$191,754
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U19AI168643-04 5360
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U19AI168643-04 5360
Patents
No Patents information available for 5U19AI168643-04 5360
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U19AI168643-04 5360
Clinical Studies
No Clinical Studies information available for 5U19AI168643-04 5360
News and More
Related News Releases
No news release information available for 5U19AI168643-04 5360
History
No Historical information available for 5U19AI168643-04 5360
Similar Projects
No Similar Projects information available for 5U19AI168643-04 5360